UAE Anti-Monopoly Drug Rules Raise Hopes for Cheaper Healthcare and Fewer Medicine Shortages
Dubai, United Arab Emirates — New regulations introduced by the Emirates Drug Establishment (EDE) aimed at breaking monopolies in the pharmaceutical supply chain could significantly reduce healthcare costs and improve access to essential medicines across the UAE, doctors and healthcare experts say.
The rules, announced this week, require pharmaceutical manufacturers to appoint more than one authorised agent for each medical product registered in the country — a move designed to increase competition, strengthen supply resilience, and prevent single distributors from controlling availability or pricing.
Healthcare professionals say the reform could mark a turning point for patients who have faced recurring shortages, high prices, and limited treatment options in recent years.
Tackling Drug Shortages and Supply Disruptions
Hospitals and pharmacies in the UAE have struggled intermittently to secure critical medications due to global supply chain disruptions, manufacturing delays, and sudden spikes in demand linked to international health trends and crises.
The most visible shortages occurred during 2023 and 2024, particularly involving GLP-1 medications used to treat diabetes and obesity. Drugs such as Ozempic, Wegovy, and Mounjaro became difficult to obtain as demand for off-label weight-loss use surged globally.
As a result, many patients with diabetes reported difficulty accessing their prescribed medication at pharmacies in Dubai and Sharjah.
Shortages have also affected medications for Attention Deficit Hyperactivity Disorder (ADHD), as well as antidepressants such as Prozac and Ranitidine, heightening concerns about continuity of care.
How the New System Works
Under the new EDE mechanism, pharmaceutical companies will be prohibited from relying on a single exclusive distributor in the UAE. Instead, each medical product must have multiple authorised local agents, ensuring that if one supplier encounters logistical or operational problems, others can maintain supply.
Dr Fatima Al Kaabi, Director General of the Emirates Drug Establishment, said the legislation would modernise how medicines are distributed and strengthen the country’s ability to respond to evolving health challenges.
“The legislation will play a key role in regulating medical product distribution, improving supply management efficiency and enhancing system resilience,” she said.
She added that the UAE is positioning itself to attract increased pharmaceutical investment and expand its role as a regional and global hub for drug manufacturing and distribution.
Why Market Competition Matters in Healthcare
Experts say monopolistic control in pharmaceutical markets often leads to higher prices, reduced availability, and increased vulnerability to supply disruptions.
A monopoly can arise when a company holds patent protection or exclusive marketing rights — an arrangement intended to reward innovation and research. However, when distribution is limited to a single agent, the system becomes fragile.
Dr Malaz Yabrodi, an internal medicine specialist at Medcare Hospital Sharjah, said lack of competition leaves patients exposed.
“Without competition, companies can set prices with limited market pressure,” she said. “This often results in high drug prices, financial strain on healthcare systems, and reduced medication adherence.”
She added that if one manufacturer or distributor experiences regulatory delays, production issues, or transport disruptions, shortages can rapidly emerge — particularly dangerous for essential medicines such as cancer treatments, insulin, or critical antibiotics.
Lessons From Global Markets
The UAE’s approach aligns with global efforts to curb anti-competitive behaviour in the pharmaceutical industry.
In China, authorities introduced anti-monopoly measures in 2025 targeting so-called “reverse payment” agreements, where brand-name drug companies compensated generic manufacturers for delaying market entry.
In the United States, the Federal Trade Commission closely scrutinises pharmaceutical mergers and distribution practices, while the European Union actively investigates pay-for-delay deals and abuses of market dominance.
Meanwhile, India, one of the world’s largest producers of generic medicines, uses strict competition laws to ensure affordable access to drugs domestically and internationally.
Relief for Doctors and Mental Health Patients
For clinicians, the new policy offers greater flexibility in treatment decisions.
Dr Sriram Raghavendran, a psychiatrist at Canadian Specialist Hospital, said reliance on a single distributor often forces doctors to alter treatment plans when medications run out.
His patients, particularly those on psychotropic medications, frequently experience distress when drugs go out of stock, including withdrawal symptoms and relapse.
“This policy ensures that if one agent faces delays, others can step in,” he said. “That means steady availability of mood stabilisers, antidepressants and antipsychotics.”
He added that increased competition among distributors is expected to gradually reduce prices, making long-term psychiatric care more affordable.
Patients Welcome the Change
Patients across the UAE say the reforms could ease both emotional and financial strain.
Victoria McKeown, who takes fluoxetine to manage anxiety linked to autism, described the stress of repeated shortages.
“Every month there’s this frantic scramble to track down medication,” she said. “For those of us on controlled prescriptions, the pressure is enormous.”
Another Dubai resident, Samer Batter, said the changes could reduce his monthly Dh600 medication bill for heart and cholesterol treatments.
“There was a time I couldn’t get Warfarin, a life-saving blood thinner,” he said. “When I was forced to switch brands, it nearly caused a medical emergency.”
A Shift Toward a More Resilient System
Health analysts say the UAE’s new anti-monopoly framework could strengthen supply security, lower costs, and improve patient outcomes — provided enforcement remains consistent.
By diversifying distribution channels and encouraging fair competition, the policy aims to ensure that no single company’s failure determines whether patients receive critical care.
For many residents and healthcare professionals, the reforms signal a long-awaited step toward a more resilient, patient-centred pharmaceutical system in the UAE.